Stellenwert bildgebender Verfahren für die Therapie der Patienten mit Parkinsonsyndrom

Zusammenfassung

Die Sicherheit der Diagnose Morbus Parkinson bleibt in der Frühphase auch weiterhin unbefriedigend. Die Darstellung der Dopamin-Transporter-Bindung mit DatSCAN^® und SPECT kann einen wichtigen Beitrag leisten, um zumindest die Patienten zu identifizieren, die nicht von einer dopamimetischen Therapie profitieren werden. Die Kosten für eine solche Untersuchung müssen in Beziehung zu den Kosten für irrtümlich verordnete Medikamente gesetzt werden.

Summary

The accuracy of the diagnosis of Parkinson's disease early in the course of the disease remains a clinical challenge. Imaging of dopamine transporters with DatSCAN® and SPEC tomography contributes to identifying patients without nigral degeneration and thus helps preventing unnecessary and potentially harmful treatments. The cost of these imaging procedures needs to be set against the cost of unnecessary medication.

Schlüsselwörter

Morbus Parkinson - dopaminergene Neurone - DaT-SCAN - SPEC-Untersuchung

Key words

Morbus Parkinson - dopaminergic neurons - DaT-SCAN - SPEC-analysis

Literatur

• 1 Hughes A J, Daniel S E, Kilford L, Lees A J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.  J Neurol Neurosurg Psychiatry. 1992;  55 181-184
• 2 Gibb W R, Lees A J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 1988;  51 745-752
• 3 Hughes A J, Daniel S E, Ben-Shlomo Y, Lees A J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.  Brain. 2002;  125 861-870
• 4 Parkinson Study Group . A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study.  Clin Neuropharmacol. 2000;  23 34-44
• 5 Fahn S, Oakes D, Shoulson I. et al . Levodopa and the progression of Parkinson’s disease.  N Engl J Med. 2004;  351 2498-2508
• 6 Oertel W H, Wolters E, Sampaio C. et al . Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET study.  Mov Disord. 2006;  21 343-353
• 7 Whone A L, Watts R L, Stoessl A J. et al . Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study.  Ann Neurol. 2003;  54 93-101
• 8 Catafau A M, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes.  Mov Disord. 2004;  19 1175-1182
• 9 Hesse S, Oehlwein C, Barthel H. et al . Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.  J Neural Transm. 2006;  113 1177-1190
• 10 Benamer H T, Patterson J, Wyper D J. et al . Correlation of Parkinson’s disease severity and duration with 123I-FP- CIT SPECT striatal uptake.  Mov Disord. 2000;  15 692-698
• 11 Rajput A H, Moghal S, Rajput A. Parkinson’s disease and essential tremor.  Neurology. 1994;  44 778
• 12 Benamer T S, Patterson J, Grosset D G. et al . Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.  Mov Disord. 2000;  15 503-510
• 13 Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism.  Mov Disord. 2003;  18, Suppl 7 28-33
• 14 Gerschlager W, Bencsits G, Pirker W. et al . [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease.  Mov Disord. 2002;  17 518-523
• 15 Scherfler C, Seppi K, Donnemiller E. et al . Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson’s disease.  Brain. 2005;  128 1605-1612
• 16 Schwarz J, Tatsch K, Arnold G. et al . 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.  Neurology. 1993;  43 S17-20
• 17 Dodel R C, Hoffken H, Moller J C. et al . Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson’s disease: a decision-analytic approach.  Mov Disord. 2003;  18, Suppl 7 52-62